You just read:

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

News provided by

DelMar Pharmaceuticals, Inc.

Feb 20, 2019, 05:30 ET